Avadel Pharmaceuticals plc (AVDL)

followers · Follow

Sector:	HEALTH CARE
Industry:	BIOTECHNOLOGY & LIFE SCIENCES
SIC:	PHARMACEUTICAL PREPARATIONS
CEO:	Gregory J. Divis
Employees:	70
Web site:	avadel.com
BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN, L2, 15 636-449-1830

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

Please log in first to see chart

Avadel Pharmaceuticals plc YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available